Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial

Table 3 GLMM estimated effects of changes in Primary and Secondary Outcomes from Baseline to Week 52

Outcome	PC-rTMS	Sham-rTMS	rTMS*group interaction F-test	rTMS*group interaction p-value
Outcome	Mean [95%CI]	Mean [95%CI]	rTMS*group interaction F-test	rTMS*group interaction p-value
CDR-SB	1.36	2.45	F_4,144.9 = 2.60	0.038*
CDR-SB	[0.68 2.04]	[1.85 3.05]	F_4,144.9 = 2.60	0.038*
ADAS-Cog ^a	5.9	10.4	F_4,139.7 = 2.95	0.022*
ADAS-Cog ^a	[3.72 8.08]	[7.34 13.46]	F_4,139.7 = 2.95	0.022*
MMSE ^a	-1.1	-3.9	F_4,141.9 = 2.43	0.051
MMSE ^a	[-2.43 0.23]	[-5.87 -1.93]	F_4,141.9 = 2.43	0.051
ADCS-ADL	-1.5	-11.6	F_4,140.4 = 6.70	< 0.001*
ADCS-ADL	[-4.51 1.51]	[-14.97 -8.23]	F_4,140.4 = 6.70	< 0.001*
NPI	3.28	6.91	F_4.147.6 = 2.44	0.049*
NPI	[-0.42 6.98]	[3.11 10.71]	F_4.147.6 = 2.44	0.049*
FAB ^a	-0.89	-0.85	F_4,140.8 = 1.59	0.180
FAB ^a	[-2.28 0.5]	[-2.76 1.06]	F_4,140.8 = 1.59	0.180

ISSN: 1758-9193